That's a completely nutty interpretation. The FDA has an accelerated approval pathway which is part of their approval structure. So of course they "support" it, they WROTE it. So to say that that was what Mesoblast was referring to is nonsensical.
What is wrong is to suggest or imply that "the FDA supports accelerated approval for Rexlemestrocel for patients with LVADs" when the feedback from the FDA was actually conditional. The trial results MAY support accelerated approval. But I really think that's doubtful.
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-445
-
- There are more pages in this discussion • 105 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |